Key Takeaways TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action, with effects observed as early as 8 hours after administration (the earliest assessment time) and a short duration of effect of 2-3 weeks. Regulatory filings seeking approval for TrenibotE remain under review in other countries worldwide. Year to date, shares of AbbVie have plunged 12% compared with the industry's decline of 5.3%. ABBV's Struggling Aesthetics Segment AbbVie is seeing declini ...